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Abstract: Intense sweeteners (IS) are often marketed as a healthier alternative to sugars, with the
potential to aid in combating the worldwide rise of diabetes and obesity. However, their use has
been counterintuitively associated with impaired glucose homeostasis, weight gain and altered gut
microbiota. The nature of these associations, and the mechanisms responsible, are yet to be fully
elucidated. Differences in their interaction with taste receptors may be a potential explanatory factor.
Like sugars, IS stimulate sweet taste receptors, but due to their diverse structures, some are also able
to stimulate bitter taste receptors. These receptors are expressed in the oral cavity and extra-orally,
including throughout the gastrointestinal tract. They are involved in the modulation of appetite,
glucose homeostasis and gut motility. Therefore, taste genotypes resulting in functional receptor
changes and altered receptor expression levels may be associated with metabolic conditions. IS and
taste receptors may both interact with the gastrointestinal microbiome, and their interactions may
potentially explain the relationship between IS use, obesity and metabolic outcomes. While these
elements are often studied in isolation, the potential interactions remain unexplored. Here, the current
evidence of the relationship between IS use, obesity and metabolic outcomes is presented, and the
potential roles for interactions with taste receptors and the gastrointestinal microbiota in modulating
these relationships are explored.
Keywords: sweetener; non-nutritive sweetener; taste receptor; gut microbiome; obesity; metabolism;
gut hormone
1. Introduction
Intense sweeteners (IS) are many times sweeter than sugar, and therefore can be used in drastically
smaller amounts, resulting in little to no energy contribution [1]. Sweeteners can be classified in
multiple ways. IS are defined here to refer to artificial and natural sweeteners that are more than
30 times sweeter than sucrose [1]. IS are promoted as a healthful alternative to sugars and regarded
as a safe means to combat the increasing incidence of obesity and diabetes when used within their
acceptable daily intake (ADI) levels [1,2]. IS are commonly used; for example, in the United States,
41% of adults and 25% of children report daily IS consumption (n = 16,942) [3]. However, despite
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their reduced energy values, epidemiological and interventional evidence now suggests that regular IS
consumption is linked to obesity and related issues [4–8].
IS have higher relative sweetness compared to sucrose (Table 1). This means much smaller
amounts are required. This is due to higher binding affinity to sweet receptors. This higher intensity,
combined with incomplete metabolism, accounts for their negligible energy contribution [9]. While
there are over 115 plant compounds with reported sweetness [10], there are a limited number of
commonly used natural and artificial sweeteners. The properties, relative sweetness and ADIs of IS
currently approved for use in Australia and New Zealand [1], the United States [11] and Europe [12]
are described in Table 1. Sugar alcohols are another important commercial sweetener; however, they
are generally less sweet than sugar and often used for their other properties (thickening, stabilizing);
as such, they are not included in this review [1].













(mg/ kg bw/ d)
Acesulphame K Artificial Acetoacetic acidand potassium 200× 15 15 9
Advantame Artificial Aspartame (below) andvanillin 20,000× 5 32.8 5
Alitame Artificial Aspartic acid andalanine 2000× 1 Not approved Not approved













extract 250–400× No ADI No ADI Not approved










300× 5 15 5
Stevia Natural Steviol glycosides fromStevia rebaudiana 200–300× 4 4 4
Sucralose Artificial Sucralose 600× 15 5 15
Thaumatin Natural Thaumatococcus danielliifruit extract 2000–3000× No ADI Not approved No ADI
AU, Australia; US, United States; EU, Europe; ADI, acceptable daily intake; bw, body weight; d, day.
IS, like sugars, bind to sweet taste receptors (T1Rs) on the tongue. Importantly, IS may also activate
bitter oral receptors (T2Rs). Both T1Rs and T2Rs are G-protein coupled taste receptors. The T1R
family consists of three different receptors. T1R1 and T1R3 heterodimerise detect umami, and T1R2
and T1R3 are involved in the detection of sweet compounds. The sweet receptor can detect different
sweet ligands via different binding domains [13]. These receptors detect foods that are high energy
and/or enjoyable [14]. Bitter compounds are detected by the T2R family of receptors. There are at least
25 functional human receptors capable of detecting hundreds of different bitter compounds [15]. Bitter
receptors are involved in protection from the ingestion of bacteria and potential toxins, which relates
to their relatively large numbers.
These receptors are also expressed throughout the gastrointestinal (GI) tract, where they are
involved in the modulation of multiple metabolic processes, including glucose homeostasis, satiation
and gut motility [16–18]. This has sparked recent interest in the roles for taste receptors in the
development of obesity and related metabolic disorders [18–20]. Furthermore, the composition
of the gut microbiome is known to be associated with the progression of obesity, diabetes and
associated metabolic conditions [21–24]. Importantly, there is evidence to suggest that health issues
like cardiovascular disease, metabolic syndrome and non-alcoholic fatty liver disease may also be
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associated with IS use [8,25], potentially via the activation of gastrointestinal taste receptors and
subsequent altered hormone secretion, and/or perturbations to the intestinal microflora.
It is likely that there are multiple factors influencing the relationship between IS consumption,
obesity and metabolic outcomes. However, these are yet to be fully elucidated. Importantly, reverse
causality bias may explain some of these associations between IS use and metabolic dysfunction.
However, as identified in an extensive review of the subject, the consistently identified association,
coupled with the fact that the majority of studies take into account key potential confounders, suggests
that reverse causality does not fully explain the increased risk [26]. Therefore, other biologically plausible
mechanisms, such as the potential interactions between IS, taste receptors and the gastrointestinal
microbiota, need to be considered. While the role of each of these elements in obesity and metabolic
regulation have each previously been considered, their interactions largely remain to be investigated.
Therefore, the current evidence of the relationship between IS use, obesity and metabolic outcomes is
presented here, and the potential roles for interactions with taste receptors and the gastrointestinal
microbiota in modulating these relationships are explored.
2. Weight and Intense Sweetener Consumption in Humans
IS consumption has been linked to weight gain and obesity in humans [5]. The first study to
identify the association between artificial sweetener use and weight gain was a 1986 prospective
cohort study of 78,694 women aged 50–69 [27]. This study found that artificial sweetener use was
associated with increased body weight over a 1-year period. This study grouped women into quintiles
based on initial body weight. Of the women who gained weight, IS-users in each quintile gained
significantly more than non-users (+4.79 pounds compared to +4.17 pounds (p < 0.01), respectively,
for the lowest quintile, and +8.19 pounds compared to +6.71 pounds (p < 0.001), respectively, for the
highest quintile) [27]. It is important to note that obese/overweight individuals might consume more
IS because of the widely accepted health benefits and a desire to lose weight. Nutrition data from
an Australian cross-sectional study found that, while only 12.6% of normal-weight (n = 2678) adults
consume IS daily, 25.7% of overweight (n = 2196) adults reported daily consumption of IS [28].
The majority of studies on IS and weight gain have focused on artificially sweetened beverages.
A longitudinal study of 3682 adults in the United States examining weight changes over a 7–8 year
period [29] found that overall there were significantly greater increases in body mass index (BMI)
in those who consumed artificially sweetened beverages equivalent to approximately 0.5 BMI units
(kg/m2). The same study noted that, in individuals consuming over 21 artificially sweetened beverages
per week, the average change in BMI was greater than those who did not consume artificially sweetened
beverages by more than 0.7 BMI units [29].
Other large studies have shown increases in BMI associated with consumption of IS-containing
beverages, including an Australian cohort study (4791 women; 3103 men) observed over a 13-year
period [30]. This study found that IS consumption was significantly associated with a greater 13-year
BMI increase than people who reported consuming IS less than once a month (women: 0.52 kg/m2
(95% CI 0.38, 0.67); men: 0.28 kg/m2 (95% CI 0.15, 0.43)). Additionally, a nine year prospective study
in 3682 adults highlighted a significant difference in the BMI of IS users (+1.48 kg/m) compared to
non-users (+1.01 kg/m; p < 0.0001) [31]. Furthermore, it was determined that consuming water in the
place of diet soft drink resulted in significantly greater weight loss (−8.8kg for water vs −7.6kg for the
diet soft drink consumers) in an intervention study of 62 overweight and obese people [32]. Altogether,
these studies suggest a link between consuming IS in diet soft drinks and weight gain.
Conversely, an interventional study in men and women (n = 303) over 12 weeks found that diet
soft drink consumers lost more weight (−5.95 kg) than water consumers (−4.09 kg) over the study
period [33]. Furthermore, a study of 163 obese women found that aspartame users regained less weight
(+5.4 kg) than non-users (+9.4 kg) 2 years after initial weight loss (−10 kg) [34]. Importantly, multiple
randomised control trials have found no significant association between IS-containing beverage use
and weight [35–37]. Overall, there is conflicting evidence regarding the use of sweeteners and their
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relationship to weight. These inconsistent results may be explained by the unique structures of
sweeteners and their varying potential to elicit downstream metabolic effects [38]. However, it is
difficult to assess this in studies that focus on diet soft drink consumption and weight, as the type and
quantities of sweeteners vary greatly between brands, and between drinks within brands. Importantly,
the potential mechanisms involved in the relationship between weight gain and sweeter use likely
relate to altered metabolic hormone secretion in response to IS, and subsequent metabolic dysfunction.
3. The Metabolic Effects of Intense Sweeteners
IS were developed to combat obesity and insulin resistance. In contrast, their use is now
associated with not only potential weight gain, but altered glucose homeostasis, decreased satiety
signalling, increased food intake and, interestingly, an altered gut microbiome [39,40]. IS appear to
have widespread physiological effects, which have been extensively reviewed by Burke and Small,
2015 [41], Hunter et al., 2017 [38], Liauchonak et al., 2019 [42] and Swithers, 2013 [4]. In regard to
metabolism, the weight gain and disrupted glucose homeostasis associated with IS consumption may
be explained by the alteration of levels of glucagon-like peptide-1 (GLP-1). GLP-1 is a hormone that is
secreted from intestinal epithelial endocrine cells in response to food intake. Its most notable role is in
stimulating insulin secretion, but it is also involved in regulating appetite and food intake [43].
Altered GLP-1 secretion has been shown in rats (n = 72) exposed to saccharin [44]. These animals
were on a high-fat, high-sugar diet, and provided with yoghurt sweetened with either saccharin
(0.3% w/w) or glucose (20% w/w). The IS-consuming rats gained significantly more weight and had
a significantly higher food intake (p < 0.05) after 28 days than the rats who consumed the glucose
sweetened yoghurt, despite there being no significant differences between their starting weights. After
these 28 days, fasting animals were given a glucose tolerance test (5 g of 20% glucose solution). At 6
and 18 min after glucose presentation, rats previously exposed to saccharin has significantly higher
blood glucose (p < 0.05) and significantly lower GLP-1 (p < 0.05) than rats previously exposed to
glucose sweetened yoghurt [44]. This study demonstrates the ability of IS exposure to affect weight,
food intake, blood glucose and GLP-1 secretion in an animal model.
Disrupted glucose homeostasis was also identified in rodents in response to IS consumption.
This study examined the effects of ad lib water compared to water with 5–7 mg/kg/d aspartame on rats
(n = 44). These animals were also separated into standard chow diets and high-fat diets. Regardless of
diet and body composition, aspartame-consuming animals had significantly elevated fasting blood
glucose levels (p < 0.05) and impaired insulin function (p < 0.05) [45]. Further, in mice (n = 20)
whose drinking water contained either water only, caloric sweeteners (10% glucose or 10% sucrose) or
commercial artificial sweeteners (5% saccharin plus 95% glucose, 5% sucralose or 4% aspartame) made
to 10% solutions, all IS-consuming groups developed significant glucose intolerance (p < 0.001) at
11 weeks [46]. Overall, these data suggest that IS consumption alters glucose homeostasis in rodents.
It is therefore not unexpected that IS consumption may be associated with the development
of type 2 diabetes in humans. A French longitudinal study in 66,118 women identified that, over
14 years, 1369 of them developed type 2 diabetes. Importantly, there was a 68% increase in the risk
of developing diabetes in that 14 years in women who consumed more than 603 mL per week of
IS-containing beverages [47]. This study suggests that regular IS consumption may increase the risk of
type 2 diabetes.
GLP-1 secretion has been shown to be altered in humans in response to IS consumption. This was
demonstrated in a randomised study of 22 healthy volunteers which compared the ingestion of either
240 mL water or diet soda 10 min prior to a glucose load (75 g; 180 min) [48]. GLP-1 area under
curve (AUC) was significantly higher in participants that consumed the diet soda AUC 24.0 +/−
15.2 pmol/L per 180 min) compared to water consumers (AUC 16.2 +/− 9.0 pmol/L per 180 min;
p = 0.003). A similar effect was shown in another single-blinded, randomised human study. In this
study, healthy participants (n = 16) were given either 24 mg sucralose in water (200 mL) or 200 mL
water alone. The AUC of GLP-1 during a 75 g, 120 min glucose tolerance test was significantly higher
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following sucralose consumption (3192 ± 1108) compared to water (2463 ± 772; p = 0.04) [49]. Overall,
these data suggest that IS consumption in the place of water may lead to altered GLP-1 secretion.
It has been further established that sucralose consumption increases plasma glucose levels and
leads to altered insulin levels [50]. This was demonstrated in a randomised crossover design, where
obese, insulin sensitive participants who did not use IS (n = 17) consumed either water (60 mL) or
sucralose in water (48 mg; 60 mL) 10 min prior to a glucose load. Sucralose consumption was associated
with increased insulin AUC (20 ± 8%; p < 0.03), increased peak plasma glucose levels (4.2 ± 0.2 vs.
4.8 ± 0.3 mmol/L; p = 0.03), increased peak insulin secretion rate (22 ± 7%; p < 0.02) and decreased
insulin clearance (7 ± 4%; p = 0.04) [50]. Altogether, sucralose consumption significantly altered insulin
responses in this cohort.
Appetite and food intake may also be affected by IS consumption. A study of 10 healthy subjects
which compared the effects of four sweet preloads (40 g glucose, 40 g tagatose/isomalt mixture, 40 g
3-O-methylglucose or 60 mg sucralose) found that consuming sucralose before a meal resulted in
reduced satiety [51]. In a similar study in 12 healthy adults, acesulfame K, aspartame and saccharin
(240 mg, 162 mg and 145 mg, respectively) preloads were assessed for effects on food intake and
appetite compared to water and glucose (50 g). It was found that the acesulfame K preload resulted
in significantly higher food intake compared to the glucose preload (p < 0.05) [52]. Additionally,
30–60 min after the aspartame preload, there was significantly increased hunger and desire to eat
compared to water (p < 0.05). These studies suggest that IS consumption before a meal may affect the
release of satiety hormones, thereby altering food intake.
Overall, there is an established counterintuitive relationship between IS consumption and
metabolic dysfunction. Differences in the metabolic effects of different sweeteners are likely to relate to
their extensive structural differences [38,53] and subsequent ability to interact with gastrointestinal
receptors. Interestingly, taste receptor genetics and altered receptor expression levels may be associated
with obesity and related metabolic conditions [20]. This appears to relate to food preferences and
intake. However, we propose that IS consumption may activate bitter and sweet receptors not only in
the oral cavity but throughout the gastrointestinal tract, thereby modifying normal metabolic functions.
4. Oral Detection of Intense Sweeteners
In the oral cavity, taste receptors may be involved in determining dietary preferences and intake.
It is important to note that taste perception is a complex and multifaceted trait. However, it is
well-established that taste genotypes play a role in taste perception, and subsequent dietary intake.
The most commonly studied human bitter taste gene is TAS2R38. The associated T2R38 receptor is
responsible for the detection of phenylthiocarbamide (PTC) and 6-n-propyl-2-thiouracil (PROP) [54].
The TAS2R38 genotype alone does not determine the ability to taste PTC and PROP [55]. However, it is
still used as a general marker of taste acuity [56]. There are two common forms of the TAS2R38 gene
which arise from three single nucleotide polymorphisms (SNPs). These polymorphisms are part of a
haplolock, and result in the amino acid substitutions proline-alanine-valine (PAV; associated with tasting
PTC and prop) or alanine-valine-isoleucine (AVI; associated with not tasting PTC or PROP). This gives
rise to three common TAS2R genotypes: PAV homozygotes (super tasters), heterozygotes (tasters) or
AVI homozygotes (non-tasters). Findings from a recent systematic review of the genetic background
of taste perception highlighted significant associations between three TAS2R38 variants (rs713598,
rs1726866, rs10246939) and bitter and sweet taste preferences [57]. Furthermore, multiple studies have
identified a relationship between TAS2R38 and BMI and/or food intake [58–63]. Importantly, some IS
have the ability to activate both sweet (T1Rs) and bitter (T2Rs) taste receptors [64] (Table 2).
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Table 2. Common intense sweeteners that activate bitter taste receptors.
Name Known to Activate T2Rs Sources





Cyclamate T2R1, T2R31, T2R38 T2R43 Behrens et al., 2017 [67]; Meyerhof et al., 2010 [66]
Monk fruit extract No
Neotame No
Neohesperidine DC No
Saccharin T2R8, T2R43, T2R31 Kuhn et al., 2004 [64]; Meyerhof et al., 2010 [66]
Stevia T2R4, T2R14 Acevedo et al., 2016 [68]; Hellfritsch et al., 2012 [69]
Sucralose No
Thaumatin No
Oral taste receptor expression partly determines dietary intake, and expression may be modulated
by dietary exposures or health conditions. A murine study which compared taste receptor expression
between lean mice and mice with diet-induced obesity found that the sweet receptor (T1R2) and a
bitter receptor (T2R118) were significantly down-regulated (p < 0.05) on the tongues of mice with
diet induced obesity compared to wild type mice. Interestingly, the expression of these receptors in
genetically obese mice was not significantly different from wild type mice [70]. This suggests that
the expression of select taste receptors decreases in response to diet-induced obesity. Subsequently,
this may lead to altered food intake (e.g., increased sugar consumption) and associated detrimental
health effects. Therefore, it is hypothesised that a similar pattern of sweet receptor under-expression
may also occur following IS consumption, resulting in the overconsumption of sugar.
Interestingly, IS consumers may have a higher sugar intake compared to water consumers. A cross
sectional study on 7026 children in the US assessed differences in energy and macronutrient intake
between consumers of IS-sweetened beverages, sugar-sweetened beverages or both, compared to water
consumers. All three groups of sweetened beverage consumers reported significantly higher energy
intake (p < 0.05), and a significantly higher intake of total sugars and added sugars (p < 0.05) [71].
Additionally, a study in 64 Canadian women, which grouped subjects based on regular sweetener
intake (both IS and nutritive sweeteners), found that people who regularly consume larger amounts of
sweeteners had a significantly greater preference for sweeter beverages (p < 0.05), which correlates with
a higher intake of sugar [72]. There are several mechanisms by which consumption of sweeteners may
increase the total intake of sugars [4,73], one of which may relate to altered taste receptor expression in
response to IS consumption.
Genetic variation may also modulate dietary intake. Genotypes that lead to functional variations
may result in reduced/improved taste sensation. In turn, this may lead to altered preferences [74].
In this way, TAS1R polymorphisms may alter the relative sweetness of IS [75,76], and therefore modify
IS consumption between individuals [77,78]. Similarly, functional polymorphisms in TAS2R genes may
also affect the bitterness of certain IS. In a study that genotyped participants (n = 108) and asked them
to rate acesulphame K bitterness, it was shown that polymorphisms in the TAS2R9 (rs3741845) and
TAS2R31 (rs10772423; rs10845293) genes were significantly associated with the perceived bitterness of
acesulfame K (p = 0.009, p = 0.010 and p = 0.032, respectively) [65]. Further, this group modelled the
combined effects of one TAS2R9 genotype and one TAS2R31 genotype, and found that this combination
explained 13.4% of acesulphame K bitterness (p < 0.001) [65].
Similarly, in a study (n = 55) which analysed the relationship between TAS2R43-W35 and
TAS2R44-W35 genotypes and saccharin bitterness, it was determined that individuals carrying at least
one of these alleles were significantly more sensitive to the bitterness of saccharin than non-carriers
(mean threshold 4.2 mM versus 25.7 mM, respectively; p < 0.0003) [79]. Furthermore, the combined
hT2R43 and hT2R44 haplotype effect explains approximately 34% of the total variance in sensitivity to
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the bitterness of saccharin (p < 0.001) [79]. Overall, taste receptor expression and genotype appear
to play a role in determining IS preferences and intake. These preferences may then influence diet
and metabolic health status. Therefore, genetic variation in taste receptors may modulate the risk for
obesity and associated conditions by determining IS intake.
5. The Role of Extra-Oral Receptors in Detecting and Responding to Intense Sweeteners
Taste receptors are not only expressed in the oral cavity but also throughout the body [80].
Recently, human taste receptors have been identified in vastly different organs, including the brain,
heart, urethra, adipose and lungs [81]. Importantly, in the respiratory tract, T2Rs detect bacteria and
bacterial quorum sensing molecules, and initiate protective immune responses [82–85]. Therefore,
taste receptors within the gastrointestinal tract may also interact with the microbiota. In humans, there
are at least 3 different T2Rs expressed in the gastrointestinal tissues [86]. Upon activation, extra-oral
T2Rs regulate the secretion of metabolic hormones involved in appetite, energy intake, gut motility and
glucose homeostasis [16–18,20,86–91]. These hormones include ghrelin (a hunger-inducing hormone),
GLP-1, GIP (glucose-dependent insulinotropic polypeptide; involved in insulin regulation), CCK
(cholecystokinin; involved in satiation and gut motility) and PYY (peptide tyrosine tyrosine; involved
in gastric motility and food intake). These four hormones are secreted in different quantities along
the gastrointestinal tract and work together to regulate food intake, glucose homeostasis and gut
motility [92].
As well as the previously discussed effects of oral taste receptor stimulation and subsequently
altered food intake, extra-oral T2R stimulation by IS may also have metabolic consequences. A study
on human intestinal enteroendocrine cells demonstrated that not only is T2R9 is expressed in these
cells but also a T2R9 ligand was found to stimulate GLP-1 secretion [87]. This study also looked at the
relationship between the TAS2R9 genotype and diabetes in 953 participants from the Amish Family
Diabetes study. It was determined that the TAS2R9-rs3741845 T allele was significantly associated with
a higher insulin AUC (858.2 ± 44.2 vs. 739.2 ±1 9.4 mmol/L; p = 0.006) and significantly higher glucose
AUC (21.0 ± 0.3 vs. 19.8 ± 0.2 mmol/L; p = 0.036) [87]. This effect was likely due to altered GLP-1
secretion. Importantly, T2R9 is known to be activated by the IS acesulphame K (Table 1) [65]. Given
this, we propose that IS like acesulphame K may disrupt glucose homeostasis by activating extra-oral
bitter receptors and subsequently altering GLP-1 secretion.
When by-passing the oral cavity, IS elicit very different hormonal responses to caloric sweeteners.
A randomised, double-blind crossover study in 12 healthy volunteers investigated the effects of
intragastric administration of acesulfame K (220 mg) compared to nutritive sweeteners (50 g glucose
and 25 g fructose) and water. It was determined that there was an initially stronger increase in
satiety, followed by a significantly larger increase in hunger in response to acesulfame K treatment
(p < 0.05) compared to water [93]. Furthermore, acesulfame K did not increase CCK secretions while
the caloric sweeteners did. Overall, this study identified that gastrointestinal hormone secretion, and
the subsequent inhibition of antral gastric motility and satiety in response to caloric sweeteners, did
not occur in response to acesulfame K [93]. This suggests that IS may activate gastrointestinal T2Rs
that are not activated by caloric sweeteners, which results in significantly different hormonal effects.
Sweet receptors may also be involved in the extra-oral detection of sweet compounds and release
of GLP-1 [89]. Importantly, lactisole, a human sweet taste receptor antagonist, completely blocks
the IS-mediated release of GLP-1 in vitro [89]. This supports a role for extra-oral sweet receptors in
glucose homeostasis. Furthermore, a study in 72 mice that looked at the effect of sweeteners (sucrose
41.66 mg/mL, sucralose 4.16 mg/mL and stevia 4.16 mg/mL) on glycaemia and appetite found that,
compared to water, sucralose treatment significantly reduced GIP secretion, glycaemia and food intake,
but increased body weight. Further, stevia treatment increased the secretion of GIP, insulin, leptin,
body weight and glycaemia [94]. These effects may be related to the potential activation of extra-oral
T1Rs and the subsequent hormone release.
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In humans, IS may also activate extra-oral T1Rs and subsequently alter intestinal hormone
secretion. The role of gastrointestinal sweet taste receptors in the modulation of appetite has previously
been identified in 35 healthy humans by analyzing the effects of lactisole (a sweet receptor blocker) on
gut hormone secretion [95]. Following either intragastric administration of 75 g of glucose in 300 mL
of water or 500 mL of a mixed liquid meal with or without lactisole or an intraduodenal perfusion
of 29.3 g glucose/100 mL; rate: 2.5 mL/min for 180 min) or a mixed liquid meal (same rate) with or
without lactisole, it was found that the lactisole treatments both resulted in significantly reduced GLP-1
and PPY secretion (p ≤ 0.05). Therefore, while artificial sweeteners like sucralose and aspartame and
its derivatives are not known to stimulate bitter receptors, they may still alter the metabolism via the
activation of extra-oral T1Rs.
In pancreatic tissues, sweet receptors detect IS and stimulate insulin secretion [96,97]. A study
that looked at the effects of IS treatment on a mouse beta-cell line and mouse islets determined that
T1R2 and T1R3 activation by sucralose, succharin and acesulfame K stimulated insulin secretion [96].
Furthermore, a murine study (n = 10) on diet-induced obesity found that a four percent IS (erythritol
and aspartame) supplementation in drinking water resulted in significantly increased body adiposity
and hyperinsulinemia compared to water controls (p < 0.05 for each) [98]. Together, these studies
suggest that IS’ activation of pancreatic T1Rs may alter insulin secretion.
Both T1Rs and T2Rs are expressed in adipose tissue, and may detect and respond to IS in this
tissue. Importantly, taste signaling molecules are involved in modulating leptin secretion [99]. It was
identified in both human and mice precursor cells lines that treatments of between 2 mM and 4.5
mM saccharin and acesulfame K stimulated adipogenesis. Furthermore, in mature adipoctyes, IS
treatment suppressed lipolysis [100]. Interestingly, this study noted that these effects were independent
of T1Rs. However, both of these IS also stimulate T2Rs (Table 2), which was not explored in this study.
Furthermore, in mice with diet-induced obesity, a 150 mg/kg/day dose of KDT501 (a T2R agonist)
resulted in a significant reduction in the weight of adipose depots (p < 0.05) [19]. In humans, TAS2R38
was overexpressed in adipocytes of obese (n = 32) compared to lean subjects (n = 18), and was found
to be involved in the cell differentiation and delipidation processes [101]. Altogether, taste receptors
appear to have roles in adipocyte metabolism that may be altered in response to IS.
Overall, in vitro and animal studies support the idea that ISs can stimulate hormone secretion from
pancreatic, adipose and enteroendocrine cells. These studies have been extensively reviewed by others,
including Brown and Rother, 2012 [102]; Bryant and Mclaughlin, 2016 [103]; Rother et al., 2018 [73];
and Han et al., 2019 [90]. However, it is important to note that there are limited studies confirming this
in humans [87,93]. For example, while multiple studies report increased insulin concentrations after IS
ingestion (sucralose or sucralose with acesulfame K) [50,104,105], others do not [51,106,107]. In two
separate studies on the effects of diet soda consumption prior to a 75 g glucose load, it was found
that IS consumption increases GLP-1 secretion. Furthermore, in nine type 1 diabetic subjects there
was a 43% higher GLP-1 AUC for IS consumers compared to water (p = 0.02) [6], and in 22 healthy
subjects, IS consumers had GLP-1 AUC of 24.0 +/− 15.2 pmol/L per 180 min versus carbonated water
consumers (AUC 16.2 +/− 9.0 pmol/L per 180 min; p = 0.003) [48]. However, intragastric administration
of sucralose (0.4 mM or 4 mM) did not affect GLP-1 or GIP release in seven healthy subjects compared
to saline [106], and intraduodenal administration of sucralose (4 mM in 0.9% saline vs control 0.9%
saline at 4 mL/min for 150 min) in 10 healthy people did not affect GLP-1 levels [108]. Additionally,
a study of 12 healthy subjects demonstrated that intragastric infusions of either aspartame, acesulfame
K or sucralose did not affect levels of GLP-1, PYY or ghrelin [109].
Overall, there is conflicting evidence from human trials regarding the effects of IS on the secretion
of gastrointestinal hormones and the potential involvement of extra-oral taste receptors. The activation
of gastrointestinal taste receptors may result in altered energy homeostasis and disrupted microbial
function [5,20,102]. As these receptors have a key role in modulating metabolic functions, it is likely
that IS-activation may lead to the subsequent secretion of key metabolic hormones. So far, this idea has
been demonstrated in cell and mouse models, but not reliably replicated in human studies.
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Differences between the type of IS are likely related to the vastly different IS structures. For example,
while aspartame (294.3 g/mol) only binds to T1Rs [76], saccharin (183.19 g/mol) is known to activate
T1Rs as well as at least three T2Rs [64,66]. Furthermore, given that taste receptor polymorphisms have
been shown to affect taste sensitivity, potentially due to altered receptor binding affinity, we propose a
similar occurrence in the gastrointestinal tract. Taste polymorphisms resulting in functional receptor
changes may alter metabolic hormone secretion in the gastrointestinal tract.
6. Intense Sweeteners and The Gut Microbiome
One mechanism by which IS may alter metabolic function is via the modulation of bacterial
composition. Conditions like obesity and insulin resistance are associated with certain gut microbial
signatures and an overall decrease in bacterial diversity [21–23,110,111]. While not an extensive
list, studies have shown that obese and overweight groups commonly show significant decreases in
Bifidobacterium (B. longum; B. adolescentis, B. animalis), Bacteroides (B. faecichinchillae, B. thetaiotaomicron and
B. vulgatus), Lactobacillus (L. casei/paracasei and L. plantarum), Faecalibacterium prausnitzii and Akkermansia
muciniphila. Conversely, the microbial signatures of obese and overweight groups include increased
Firmicutes (Blautia hydrogenotorophica, Coprococcus catus, Eubacterium ventriosum, Ruminococcus bromii,
and Ruminococcus obeum), Lactobacillus reuteri, and potential pathogens like Staphylococcus aureus,
Escherichia Shigella and E. coli and Eubacterium rectale [20,23,24,112,113]. In regard to diabetes, genera of
Bifidobacterium (B. bifidum, B. longum, B. infantis, B. animalis, B. pseudocatenulatum, B. breve), Bacteroides
(B. intestinalis, B. 20–3 and B. vulgatus), Faecalibacterium prausnitzii, Akkermansia muciniphila and Roseburia
(R. inulinivorans, Roseburia_272,) were negatively associated with T2D. Additionally, Ruminococcus
gnavus and Fusobacterium nucleatum were positively associated with T2D [21]. Overall, extensive
studies have identified significant associations between certain metabolic conditions and gut microbial
composition/function.
Importantly, IS use is strongly associated with perturbations to the intestinal microbiota in rodent
models and humans [114]. It was recently identified in vitro that the artificial sweeteners saccharin,
sucralose and acesulfame potassium have a direct bacteriostatic effect on common gut microflora
(E. coli strains) [115]. This study also examined the effects of sucralose consumption (2.5% w/v in
drinking water) on bacterial composition in mice. It was determined via 16S RNA sequencing that
sucralose consumption induced dysbiosis in mice (significantly increased Firmicutes (p < 0.05) and
significantly reduced Bacteroidetes (p = 0.117) compared to chow-only mice. Furthermore, this effect
was exacerbated when sucralose was consumed in the context of a high-fat diet [115]. Overall, this
study highlighted the detrimental effects of IS on commensal intestinal bacteria. In this way, IS
consumption may exacerbate metabolic conditions. This idea has been demonstrated in a murine study
which analysed the metabolic effects of low-dose aspartame treatment in rats. This study identified
alterations to gut bacteria, along with elevated fasting glucose levels and insulin tolerance following
an eight-week aspartame treatment (5–7 mg/kg/day, equivalent to two cans of diet soft drink; upper
daily-recommended intake = 40–50 mg/kg/day) [45]. However, the mechanism by which this occurred
remained unclear.
Similarly, there is also evidence to suggest that the natural intense sweetener stevia may disrupt
the composition and function of the gut microbiome [116–118]. Stevia extracts are not metabolised in
the upper gastrointestinal tract and therefore interact directly with colonic microbiota. It was shown
in vitro that stevia extracts enhanced the growth of bifidobacteria and lactobacilli [119], and impedes the
growth of E. coli strains in mice [115]. Furthermore, a recent murine study investigated the effects of
maternal IS consumption on offspring. It was found that maternal stevia consumption (2–3 mg/kg/day)
coupled with a high-fat diet (compared to high-fat diet only) leads to altered faecal microbiota in
dams and offspring, and significantly increased offspring percent body fat at weaning (27.3 ± 1.3
vs. 21.4 ± 2 for female offspring and 24.7 ± 1.2 vs. 21.0 ± 1.2 for male offspring; p < 0.05 for both).
Furthermore, upon receiving a microbial transplant from these offspring, germ-free mice had greater
body fat and impaired glucose intolerance compared to obese wild type mice [116]. This study confirms
Int. J. Environ. Res. Public Health 2020, 17, 4094 10 of 18
that maternal IS consumption, paired with a high-fat diet, results in metabolic dysfunction in offspring
who have not been themselves exposed to IS. Therefore, it is likely that the metabolic effects relate to
the disrupted microbiome that is passed from dam to offspring.
A similar murine study also found that stevia consumption altered gut microbiota composition.
In addition, this study demonstrated significantly increased caecal concentrations of the short-chain
fatty acids acetate (p = 0.016) and valerate (p = 0.019). Interestingly, both acetate and valerate levels
were significantly associated with increased fat mass and weight in response to stevia consumption
(p < 0.05 for each) [117]. Overall, stevia may have detrimental effects on colonic microbial function,
which may have consequences for metabolic derangements.
Furthermore, in a murine study that investigated the effects of IS consumption on body weight
and food intake, it was shown that maximum artificial sweetener consumption (saccharin (10 mg/day,
cyclamate 22 mg/day) resulted in significantly higher body weights compared to the control (p < 0.03
and p < 0.003, respectively). Interestingly, this did not correlate with altered food intake [120]. We
propose that, as identified by Suez et al. [46], this weight increase may relate to alterations to the
gut microbiota. Alternatively, the IS in this study may activate intestinal taste receptors, resulting in
metabolic derangements.
In mice whose drinking water contained either water only, caloric sweeteners (10% glucose
or 10% sucrose) or commercial artificial sweeteners (5% saccharin plus 95% glucose, 5% sucralose
or 4% aspartame) made to 10% solutions, all IS-consuming groups developed significant glucose
intolerance (p < 0.001) at 11 weeks [46]. Importantly, this effect was fully transferrable to germ-free
mice and was shown to be eliminated by antibiotic treatment. This study also showed a similar
effect of IS-induced dysbiosis on glucose intolerance in humans [46]. Data from 381 non-diabetic
individuals was assessed for correlations between IS consumption and markers of metabolic syndrome.
IS consumption was positively correlated with significantly higher levels of glycosylated haemoglobin
(HbA1C%; p < 0.002). Furthermore, 172 randomly selected subjects from this cohort were selected for
16S sequencing. Significant positive correlations between IS consumption and multiple taxonomic
classes were identified, including the Enterobacteriaceae family (p < 10−6), the Deltaproteobacteria class
(p < 10−5) and the Actinobacteria phylum (p < 0.0003). In order to identify causation, seven volunteers
who do not normally consume IS consumed 5 mg of commercial saccharin per kg (body weight) daily
for a week. It was found that four out of seven volunteers (‘responders’) developed significantly
impaired glycaemic responses (p < 0.001). Finally, stool samples from two of the responders were taken
before day 1 and after day 7. When transferred to germ-free mice, stool from NAS responders induced
significant glucose intolerance in recipient germ-free mice, compared to mice who received stool from
before day 1 [46]. Overall, this study eloquently highlights the way in which IS consumption can alter
glucose intolerance via modification of the intestinal microbiome (Figure 1).
The gut microbiome may be involved in the modulation of taste preferences and consumption
of IS via manipulation of taste receptor expression [121]. Interestingly, taste receptor expression is
altered following bariatric surgery. Along with satiety and food preferences, this surgery also alters the
gastrointestinal microbiota, as reviewed by Miras and le Roux, 2013 [122]. This suggests a link between
intestinal dysbiosis and altered taste preferences. Furthermore, germ-free mice have been shown to
have a greater number of gastrointestinal sweet receptors, and had higher preferences for sweet-tasting
foods compared to control mice [123]. Overall, the gut microbiota may alter taste preferences by
manipulating taste receptor expression, which may subsequently affect microbial composition and
alter the risk of metabolic disorders.
Metabolic conditions like insulin resistance and obesity, which are related to IS consumption and
gut dysbiosis [5,21–23,46], are also associated with certain TASR genotypes [124] and altered taste
receptor expression levels [31]. Importantly, taste receptors are activated by bacteria and bacterial
compounds [20,80–82,85,125], and can also stimulate the secretion of anti-microbial agents [126].
Furthermore, receptor expression levels may change in response to altered bacterial compositions [20],
resulting in altered metabolic functions. Given the crucial roles of taste receptors and the gut microbiome
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on metabolic health, we propose bidirectional interactions between these receptors and gastrointestinal
microbes, which are altered in response to the consumption of IS. However, further investigations are
needed to establish the mechanisms of this counter-intuitive relationship.
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7. Conclusions
Taste receptors may represent a link between the use of IS, intestinal dysbiosis, weight gain and
metabolic outcomes. While the metabolic effects of IS consumption on T1Rs have been explored
in humans [102], the pot ntial activati n of bitter receptors and the d w stream metabolic effects
of that activation have been largely overlooked. Overall, IS may alt risk for metabolic disorders
via interactions with taste receptors and int stinal microbiota. If this is the case, certain dietary or
microbial interventions may be used for the prevention or treatment of metabolic conditions related to
gastrointestinal dysbiosis and IS consumpt on. However further stud es re needed to confirm this
association in humans and define the mechanisms.
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frequency of bitter food intake, and blood biomarkers among elderly woman. Appetite 2017, 116, 57–64.
[CrossRef]
62. Lumeng, J.C.; Cardinal, T.M.; Sitto, J.R.; Kannan, S. Ability to taste 6-n-propylthiouracil and BMI in
low-income preschool-aged children. Obesity 2008, 16, 1522–1528. [CrossRef]
63. Ortega, F.J.; Agüera, Z.; Sabater, M.; Moreno-Navarrete, J.M.; Alonso-Ledesma, I.; Xifra, G.; Botas, P.;
Delgado, E.; Jiménez-Murcia, S.; Fernández-García, J.C.; et al. Genetic variations of the bitter taste receptor
TAS2R38 are associated with obesity and impact on single immune traits. Mol. Nutr. Food Res. 2016, 60,
1673–1683. [CrossRef]
64. Kuhn, C.; Bufe, B.; Winnig, M.; Hofmann, T.; Frank, O.; Behrens, M.; Lewtschenko, T.; Slack, J.P.; Ward, C.D.;
Meyerhof, W. Bitter Taste Receptors for Saccharin and Acesulfame K. J. Neurosci. 2004, 24, 10260–10265.
[CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2020, 17, 4094 15 of 18
65. Allen, A.L.; McGeary, J.E.; Knopik, V.S.; Hayes, J.E. Bitterness of the Non-nutritive Sweetener Acesulfame
Potassium Varies With Polymorphisms in TAS2R9 and TAS2R31. Chem. Senses 2013, 38, 379–389. [CrossRef]
[PubMed]
66. Meyerhof, W.; Batram, C.; Kuhn, C.; Brockhoff, A.; Chudoba, E.; Bufe, B.; Appendino, G.; Behrens, M.
The Molecular Receptive Ranges of Human TAS2R Bitter Taste Receptors. Chem. Senses 2009, 35, 157–170.
[CrossRef]
67. Behrens, M.; Blank, K.; Meyerhof, W. Blends of Non-caloric Sweeteners Saccharin and Cyclamate Show
Reduced Off-Taste due to TAS2R Bitter Receptor Inhibition. Cell Chem. Boil. 2017, 24, 1199–1204.e2. [CrossRef]
[PubMed]
68. Acevedo, W.; González-Nilo, F.; Agosin, E. Docking and Molecular Dynamics of Steviol Glycoside–Human
Bitter Receptor Interactions. J. Agric. Food Chem. 2016, 64, 7585–7596. [CrossRef] [PubMed]
69. Hellfritsch, C.; Brockhoff, A.; Stähler, F.; Meyerhof, W.; Hofmann, T.F. Human Psychometric and Taste
Receptor Responses to Steviol Glycosides. J. Agric. Food Chem. 2012, 60, 6782–6793. [CrossRef]
70. Chao, D.H.M.; Argmann, C.; Van Eijk, M.; Boot, R.; Ottenhoff, R.; Van Roomen, C.; Foppen, E.; Siljee, J.E.;
Unmehopa, U.A.; Kalsbeek, A.; et al. Impact of obesity on taste receptor expression in extra-oral tissues:
Emphasis on hypothalamus and brainstem. Sci. Rep. 2016, 6, 29094. [CrossRef]
71. Sylvetsky, A.C.; Figueroa, J.; Zimmerman, T.; Swithers, S.E.; Welsh, J.A. Consumption of low-calorie
sweetened beverages is associated with higher total energy and sugar intake among children, NHANES
2011-2016. Pediatr. Obes. 2019, 14, e12535. [CrossRef]
72. Mahar, A.; Duizer, L. The Effect of Frequency of Consumption of Artificial Sweeteners on Sweetness Liking
by Women. J. Food Sci. 2007, 72, S714–S718. [CrossRef]
73. Rother, K.I.; Conway, E.M.; Sylvetsky, A.C. How Non-nutritive Sweeteners Influence Hormones and Health.
Trends Endocrinol. Metab. 2018, 29, 455–467. [CrossRef]
74. Bachmanov, A.; Bosak, N.P.; Lin, C.; Matsumoto, I.; Ohmoto, M.; Reed, D.; Nelson, T.M. Genetics of Taste
Receptors. Curr. Pharm. Des. 2014, 20, 2669–2683. [CrossRef] [PubMed]
75. Fernstrom, J.D.; Munger, S.D.; Sclafani, A.; De Araujo, I.E.; Roberts, A.; Molinary, S. Mechanisms for
sweetness. J. Nutr. 2012, 142, 1134S–1141S. [CrossRef] [PubMed]
76. Li, X.; Bachmanov, A.; Maehashi, K.; Li, W.; Lim, R.; Brand, J.G.; Beauchamp, G.K.; Reed, D.; Thai, C.;
Floriano, W. Sweet taste receptor gene variation and aspartame taste in primates and other species. Chem.
Senses 2011, 36, 453–475. [CrossRef] [PubMed]
77. García-Bailo, B.; Toguri, C.; Eny, K.M.; El-Sohemy, A. Genetic Variation in Taste and Its Influence on Food
Selection. OMICS J. Integr. Boil. 2009, 13, 69–80. [CrossRef] [PubMed]
78. Chamoun, E.; Mutch, D.; Allen-Vercoe, E.; Buchholz, A.C.; Duncan, A.M.; Spriet, L.L.; Haines, J.; Ma, W.L.D.
On behalf of the Guelph Family Health Study A review of the associations between single nucleotide
polymorphisms in taste receptors, eating behaviors, and health. Crit. Rev. Food Sci. Nutr. 2017, 58, 194–207.
[CrossRef] [PubMed]
79. Pronin, A.N.; Xu, H.; Tang, H.; Zhang, L.; Li, Q.; Li, X. Specific Alleles of Bitter Receptor Genes Influence
Human Sensitivity to the Bitterness of Aloin and Saccharin. Curr. Boil. 2007, 17, 1403–1408. [CrossRef]
[PubMed]
80. Carey, R.M.; Lee, R.J.; Cohen, N.A.; Woodworth, B.; Poetker, D.; Reh, D. Taste Receptors in Upper Airway
Immunity. Adv. Oto Rhino Laryngol. 2016, 79, 91–102. [CrossRef]
81. Freund, J.; Lee, R.J. Taste receptors in the upper airway. World J. Otorhinolaryngol. Head Neck Surg. 2018, 4,
67–76. [CrossRef]
82. Shah, A.S.; Ben-Shahar, Y.; Moninger, T.O.; Kline, J.N.; Welsh, M.J. Motile Cilia of Human Airway Epithelia
Are Chemosensory. Science 2009, 325, 1131–1134. [CrossRef]
83. Tizzano, M.; Gulbransen, B.; Vandenbeuch, A.; Clapp, T.R.; Herman, J.P.; Sibhatu, H.M.; Churchill, M.;
Silver, W.L.; Kinnamon, S.C.; Finger, T. Nasal chemosensory cells use bitter taste signaling to detect irritants
and bacterial signals. Proc. Natl. Acad. Sci. USA 2010, 107, 3210–3215. [CrossRef] [PubMed]
84. Adappa, N.D.; Zhang, Z.; Palmer, J.N.; Kennedy, D.W.; Doghramji, L.; Lysenko, A.; Reed, D.; Scott, T.;
Zhao, N.W.; Owens, D.; et al. The bitter taste receptor T2R38 is an independent risk factor for chronic
rhinosinusitis requiring sinus surgery. Int. Forum Allergy Rhinol. 2013, 4, 3–7. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2020, 17, 4094 16 of 18
85. Lee, R.J.; Xiong, G.; Kofonow, J.M.; Chen, B.; Lysenko, A.; Jiang, P.; Abraham, V.; Doghramji, L.; Adappa, N.D.;
Palmer, J.N.; et al. T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection.
J. Clin. Investig. 2012, 122, 4145–4159. [CrossRef] [PubMed]
86. Xie, C.; Wang, X.; Young, R.; Horowitz, M.; Rayner, C.K.; Wu, T. Role of Intestinal Bitter Sensing in
Enteroendocrine Hormone Secretion and Metabolic Control. Front. Endocrinol. 2018, 9, 576. [CrossRef]
[PubMed]
87. Dotson, C.D.; Zhang, L.; Xu, H.; Shin, Y.-K.; Vigues, S.; Ott, S.H.; Elson, A.; Choi, H.J.; Shaw, H.; Egan, J.M.;
et al. Bitter Taste Receptors Influence Glucose Homeostasis. PLoS ONE 2008, 3, e3974. [CrossRef] [PubMed]
88. Janssen, S.; Laermans, J.; Verhulst, P.-J.; Thijs, T.; Tack, J.; Depoortere, I. Bitter taste receptors and α-gustducin
regulate the secretion of ghrelin with functional effects on food intake and gastric emptying. Proc. Natl. Acad.
Sci. USA 2011, 108, 2094–2099. [CrossRef]
89. Jang, H.-J.; Kokrashvili, Z.; Theodorakis, M.J.; Carlson, O.D.; Kim, B.-J.; Zhou, J.; Kim, H.H.; Xu, X.; Chan, S.L.;
Juhaszova, M.; et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like
peptide-1. Proc. Natl. Acad. Sci. USA 2007, 104, 15069–15074. [CrossRef]
90. Han, P.; Bagenna, B.; Fu, M. The sweet taste signalling pathways in the oral cavity and the gastrointestinal
tract affect human appetite and food intake: A review. Int. J. Food Sci. Nutr. 2018, 70, 125–135. [CrossRef]
91. Andreozzi, P.; Sarnelli, G.; Pesce, M.; Zito, F.P.; Alessandro, A.D.; Verlezza, V.; Palumbo, I.; Turco, F.;
Esposito, K.; Cuomo, R. The Bitter Taste Receptor Agonist Quinine Reduces Calorie Intake and Increases the
Postprandial Release of Cholecystokinin in Healthy Subjects. J. Neurogastroenterol. Motil. 2015, 21, 511–519.
[CrossRef]
92. Steinert, R.E.; Feinle-Bisset, C.; Asarian, L.; Horowitz, M.; Beglinger, C.; Geary, N. Ghrelin, CCK, GLP-1, and
PYY(3–36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After
RYGB. Physiol. Rev. 2017, 97, 411–463. [CrossRef]
93. Meyer-Gerspach, A.C.; Biesiekierski, J.R.; Deloose, E.; Clevers, E.; Rotondo, A.; Rehfeld, J.F.; Depoortere, I.; Van
Oudenhove, L.; Tack, J. Effects of caloric and noncaloric sweeteners on antroduodenal motility, gastrointestinal
hormone secretion and appetite-related sensations in healthy subjects. Am. J. Clin. Nutr. 2018, 107, 707–716.
[CrossRef]
94. Rosales, C.; Martinez-Carrillo, B.E.; Reséndiz-Albor, A.A.; Ramírez-Duran, N.; Valdés-Ramos, R.;
Mondragón-Velásquez, T.; Escoto-Herrera, J.A. Chronic Consumption of Sweeteners and Its Effect on
Glycaemia, Cytokines, Hormones, and Lymphocytes of GALT in CD1 Mice. BioMed. Res. Int. 2018, 2018,
1–15. [CrossRef] [PubMed]
95. Gerspach, A.C.; Steinert, R.E.; Schönenberger, L.; Graber-Maier, A.; Beglinger, C. The role of the gut sweet
taste receptor in regulating GLP-1, PYY, and CCK release in humans. Am. J. Physiol. Metab. 2011, 301,
E317–E325. [CrossRef] [PubMed]
96. Nakagawa, Y.; Nagasawa, M.; Yamada, S.; Hara, A.; Mogami, H.; Nikolaev, V.O.; Lohse, M.J.; Shigemura, N.;
Ninomiya, Y.; Kojima, I. Sweet Taste Receptor Expressed in Pancreatic β-Cells Activates the Calcium and
Cyclic AMP Signaling Systems and Stimulates Insulin Secretion. PLoS ONE 2009, 4, e5106. [CrossRef]
[PubMed]
97. Sternini, C.; Anselmi, L.; Rozengurt, E. Enteroendocrine cells: A site of ‘taste’ in gastrointestinal chemosensing.
Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15, 73–78. [CrossRef] [PubMed]
98. Mitsutomi, K.; Masaki, T.; Shimasaki, T.; Gotoh, K.; Chiba, S.; Kakuma, T.; Shibata, H. Effects of a nonnutritive
sweetener on body adiposity and energy metabolism in mice with diet-induced obesity. Metabolism 2014, 63,
69–78. [CrossRef] [PubMed]
99. Avau, B.; Bauters, D.; Steensels, S.; Vancleef, L.; Laermans, J.; Lesuisse, J.; Buyse, J.; Lijnen, H.R.; Tack, J.;
Depoortere, I. The Gustatory Signaling Pathway and Bitter Taste Receptors Affect the Development of
Obesity and Adipocyte Metabolism in Mice. PLoS ONE 2015, 10, e0145538. [CrossRef]
100. Simon, B.R.; Parlee, S.D.; Learman, B.S.; Mori, H.; Scheller, E.L.; Cawthorn, W.P.; Ning, X.; Gallagher, K.;
Tyrberg, B.; Assadi-Porter, F.M.; et al. Artificial Sweeteners Stimulate Adipogenesis and Suppress Lipolysis
Independently of Sweet Taste Receptors. J. Boil. Chem. 2013, 288, 32475–32489. [CrossRef]
101. Cancello, R.; Micheletto, G.; Meta, D.; Lavagno, R.; Bevilacqua, E.; Panizzo, V.; Invitti, C. Expanding the role
of bitter taste receptor in extra oral tissues: TAS2R38 is expressed in human adipocytes. Adipocyte 2020, 9,
7–15. [CrossRef]
Int. J. Environ. Res. Public Health 2020, 17, 4094 17 of 18
102. Brown, R.J.; Rother, K.I. Non-nutritive sweeteners and their role in the gastrointestinal tract. J. Clin. Endocrinol.
Metab. 2012, 97, 2597–2605. [CrossRef]
103. Bryant, C.; McLaughlin, J. Low calorie sweeteners: Evidence remains lacking for effects on human gut
function. Physiol. Behav. 2016, 164, 482–485. [CrossRef]
104. Lertrit, A.; Srimachai, S.; Saetung, S.; Chanprasertyothin, S.; Chailurkit, L.-O.; Areevut, C.; Katekao, P.;
Ongphiphadhanakul, B.; Sriphrapradang, C. Effects of sucralose on insulin and glucagon-like peptide-1
secretion in healthy subjects: A randomized, double-blind, placebo-controlled trial. Nutrition 2018, 55–56,
125–130. [CrossRef] [PubMed]
105. Sylvetsky, A.C.; Brown, R.J.; Blau, J.E.; Walter, M.; Rother, K.I. Hormonal responses to non-nutritive
sweeteners in water and diet soda. Nutr. Metab. 2016, 13, 71. [CrossRef] [PubMed]
106. Ma, J.; Bellon, M.; Wishart, J.M.; Young, R.; Blackshaw, A.; Jones, K.L.; Horowitz, M.; Rayner, C.K. Effect of
the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects. Am.
J. Physiol. Liver Physiol. 2009, 296, G735–G739. [CrossRef] [PubMed]
107. Brown, A.W.; Brown, M.M.B.; Onken, K.L.; Beitz, D.C. Short-term consumption of sucralose, a nonnutritive
sweetener, is similar to water with regard to select markers of hunger signaling and short-term glucose
homeostasis in women. Nutr. Res. 2011, 31, 882–888. [CrossRef] [PubMed]
108. Ma, J.; Chang, J.; Checklin, H.L.; Young, R.; Jones, K.L.; Horowitz, M.; Rayner, C.K. Effect of the artificial
sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects. Br. J. Nutr. 2010, 104,
803–806. [CrossRef]
109. Steinert, R.E.; Frey, F.; Töpfer, A.; Drewe, J.; Beglinger, C. Effects of carbohydrate sugars and artificial
sweeteners on appetite and the secretion of gastrointestinal satiety peptides. Br. J. Nutr. 2011, 105, 1320–1328.
[CrossRef]
110. Bäckhed, F.; Ding, H.; Wang, T.; Hooper, L.V.; Koh, G.Y.; Nagy, A.; Semenkovich, C.F.; Gordon, J.I. The gut
microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 2004, 101,
15718–15723. [CrossRef]
111. Karlsson, F.; Tremaroli, V.; Nookaew, I.; Bergström, G.; Behre, C.J.; Fagerberg, B.; Nielsen, J.; Bäckhed, F. Gut
metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498,
99–103. [CrossRef]
112. Gomes, A.C.; Hoffmann, C.; Mota, J.F. The human gut microbiota: Metabolism and perspective in obesity.
Gut Microbes 2018, 9, 1–18. [CrossRef]
113. Castañer, O.; Goday, A.; Park, Y.-M.M.; Lee, S.H.; Magkos, F.; Shiow, S.-A.T.E.; Schröder, H. The Gut
Microbiome Profile in Obesity: A Systematic Review. Int. J. Endocrinol. 2018, 2018, 1–9. [CrossRef]
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